Briefing
Serial ctDNA monitoring during adjuvant capecitabine in early triple-negative breast cancer
Phase 2 trial of adjuvant capecitabine with serial ctDNA monitoring. The registry primary outcome is the baseline level of ctDNA detection. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting